InterCure Ltd.

NASDAQ:INCR

Drug Manufacturers - Specialty & Generic

Healthcare
$3.98 -3.97%

-$0.04 today

Market cap
$51.63M
Beta
0.57
P/E (TTM)
-4.3
EPS (TTM)
-$0.64
52W Low $0.68High $1.77

Volume 0.01M

Average 0.04M

INCR Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

InterCure Ltd.NASDAQ: INCR

Research & Development · Q2 FY2025 · quarter ended Jun 2025

Research & development dips below year-ago levels

Q2 FY2025 research & development of ₪95.5K fell 12.8% year over year, behind the +10.0% change in trailing-twelve-month research & development. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at -14.9% a year.

Context

  • Research & development amounted to 0.1% of revenue in FY2025, unchanged from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -12.8% toward the trailing-twelve-month pace of +10.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2025
₪95.5K+0.0% QoQ
Last fiscal yearDec 2025
₪390K-5.8% YoY
LTMJun 2025
₪386K+10.0% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-12.8%——
1 year-5.8%——
3-year CAGR-14.9%——
5-year CAGR——
10-year CAGR——

Research & Development history

ILS · from the income statement

Latest · FY2025
390K ILS
Year-over-year change
-5.8%
4-year CAGR
-25.0%

Research & Development vs competitors

How INCR compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +10.0% is the 2nd highest of 9, against a peer median of -33.4%.
  • Research & development amounts to 0.2% of revenue for INCR, versus a peer median of 24.8%.
INCR Competitors
Research & Development for INCR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AMWLAmerican Well CorporationLTM Mar 2026$63.14M USD-22.5%-19.3%26.6%
BMEABiomea Fusion, Inc.LTM Mar 2026$48.2M USD-55.0%-0.4%—
CAMPCAMP4 Therapeutics CorporationLTM Mar 2026$37.7M USD-3.9%—958.2%
CRDLCardiol Therapeutics Inc.LTM Mar 2026CA$15.22M CAD+22.5%+0.1%—
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026$8.57M USD-44.2%-9.8%—
FBIOFortress Biotech, Inc.LTM Mar 2026$8.51M USD-76.4%-55.5%12.9%
HYFTMindWalk Holdings Corp.LTM Jan 2026CA$4.56M CAD+1.7%-13.6%24.8%
ASRTAssertio Holdings, Inc.LTM Mar 2026$1.71M USD-51.6%—1.7%
INCRInterCure Ltd.LTM Jun 2025₪386K ILS+10.0%-14.9%0.2%
Peer median (excluding INCR) —-33.4%-11.7%24.8%

Competitors are the stored peer set for INCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

ILS
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue219.68M388.68M355.55M238.85M270.2M
Cost of Revenue128.55M233.6M250.46M208.61M237.02M
Gross Profit91.13M155.08M105.1M30.23M33.18M
Gross Margin41.5%39.9%29.6%12.7%12.3%
Research & Development1.24M632K388K414K390K
Selling, General & Admin53.46M97.32M86.24M84.63M80.41M
Operating Expenses62.95M104.46M146.66M97.44M26.45M
Depreciation & Amortization7.39M11.7M13.17M15.37M17.15M
EBITDA31.17M70.23M(23.9M)(51.31M)(7.29M)
EBITDA Margin14.2%18.1%-6.7%-21.5%-2.7%
Operating Income28.19M50.63M(41.57M)(67.21M)6.73M
Operating Margin12.8%13.0%-11.7%-28.1%2.5%
Interest Income130K844K4.55M2.7M1.56M
Interest Expense5.05M14.69M24.22M20.65M19.66M
Other Income / Expenses(9.45M)(6.79M)(19.72M)(20.12M)(50.84M)
Income Before Tax18.74M43.84M(61.29M)(87.32M)(44.1M)
Pre-Tax Margin8.5%11.3%-17.2%-36.6%-16.3%
Income Tax Expense11.44M93K2.25M(14.53M)(7.32M)
Net Income4.69M44.82M(61.96M)(67.8M)(35.71M)
Net Margin2.1%11.5%-17.4%-28.4%-13.2%
EPS (Basic)0.120.99(1.36)(1.42)(0.63)
EPS (Diluted)0.110.99(1.36)(1.42)(0.63)
Weighted Avg Shares38.49M45.35M45.56M47.77M56.8M
Weighted Avg Shares (Diluted)40.84M45.35M45.57M47.77M56.8M

InterCure Ltd.

NASDAQ:INCR

Intrinsic Alpha fair value

Locked

Current Price

$3.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.